The Role of Anti-IgE Therapy in Combination with Allergen Specific Immunotherapy for Seasonal Allergic Rhinitis

BioDrugs ◽  
2007 ◽  
Vol 21 (6) ◽  
pp. 403-410 ◽  
Author(s):  
Philippe Stock ◽  
Claudia Rolinck-Werninghaus ◽  
Ulrich Wahn ◽  
Eckard Hamelmann
2011 ◽  
Vol 22 (1) ◽  
pp. 15-23 ◽  
Author(s):  
Cengiz Kirmaz ◽  
Ozlem Ozenturk Kirgiz ◽  
Papatya Bayrak ◽  
Ozge Yilmaz ◽  
Seda Vatansever ◽  
...  

2005 ◽  
Vol 5 (4) ◽  
pp. 661-666 ◽  
Author(s):  
Ümran Soyoğul Gürer ◽  
Suna Büyüköztürk ◽  
Şükrü Palandüz ◽  
Erkan Rayaman ◽  
Bahattin Çolakoglu ◽  
...  

2019 ◽  
pp. 66-71
Author(s):  
L. P. Sizyakina ◽  
E. N. Zabrodskaya ◽  
I. A. Andreeva

Seasonal allergic rhinitis (SAR) remains an important medical and social problem, the importance of which is determined by the steady growth of morbidity, the expansion of the spectrum of pollen sensitisation, the development of complications in the form of otitis, sinusitis, eustachitis, and often low efficiency of standard therapy. One of the reasons for the complication of allergic diseases in general and SAR in particular is the combination of allergy and secondary immune deficiency syndrome (SID). In order to form an understanding of the possibilities of allergen-specific immunotherapy (ASIT) optimization, an analysis of the clinical, immunological and allergic status of patients suffering from SAR with concomitant SID syndrome who received two ASIT courses. All patients (40 people aged 18-60 years) were divided into two groups: those receiving only SIT (20 people) and those receiving gamma-D-glutamyl triptofan (GDGT) immunomodulator treatment (20 people) in addition to standard therapy. The results of the study clearly indicate a sufficiently high therapeutic efficacy of the used approach of combination of preventive immunocorrection and ASIT, which consists in a reliable reduction of morbidity and duration of ARVI episodes, more significant effectiveness of ASIT. The basis of the positive effect of preventive therapy of GDGT is the restoration of functional parameters of the immune system.


2015 ◽  
Vol 12 (6) ◽  
pp. 54-67
Author(s):  
N M Nenasheva

Bronchial asthma is a heterogeneous disease in terms of the phenotypes, but the majority of patients, both children and adolescents, and adults suffer from IgE-dependent (atopic) asthma. This asthma phenotype most often is associated with allergic rhinitis, which defines systemic therapy for both diseases. The allergen-specific immunotherapy (SIT) meets that approach best of all. SIT is viewed as a treatment not for a specific nosology (rhinitis, asthma or atopic dermatitis), but for an allergen. The epidemiology and the etiology of atopic asthma, role of SIT in treatment of asthma, efficacy, safety, and basic mechanisms are discussed in the article.


Sign in / Sign up

Export Citation Format

Share Document